Last quarter (Q3 2023), Kiora Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Kiora Pharmaceuticals's net income was $-6.29M. See Kiora Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 12.06K	$ 2.69M	$ 1.65M
Cost of Revenue	$ -100.00K	-	-	-	-	-
Gross Profit	$ 100.00K	-	-	-	-	-
Operating Expense	$ 10.47M	$ -12.31M	$ 16.94M	$ 8.22M	$ 9.80M	$ 12.50M
Operating Income	$ -10.18M	$ -11.73M	$ -10.67M	$ -8.21M	$ -7.11M	$ -10.84M
Net Non Operating Interest Income Expense	$ 95.00K	$ 48.29K	$ -5.71K	$ 19.15K	$ 107.74K	$ 119.32K
Other Income Expense	$ 1.81M	$ 2.00M	$ 1.52M	$ 113.72K	-	-
Pretax Income	$ -7.46M	$ -13.70M	$ -16.70M	$ -8.08M	$ -7.00M	$ -10.73M
Tax Provision	-	$ -113.01K	$ -304.78K	$ 12.05K	$ 95.40K	$ 86.05K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -10.78M	$ -13.58M	$ -16.39M	$ -8.09M	$ -7.10M	$ -10.81M
Basic EPS	$ -2.68	$ -18.55	$ -1.77	$ -1.77	$ -2.23	$ -4.57
Diluted EPS	$ -2.68	$ -18.55	$ -1.77	$ -1.77	$ -2.23	$ -4.57
Basic Average Shares	$ 12.26M	$ 732.30K	$ 9.24M	$ 4.58M	$ 3.18M	$ 2.37M
Diluted Average Shares	$ 12.26M	$ 732.30K	$ 9.24M	$ 4.58M	$ 3.18M	$ 2.37M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 10.37M	$ -12.31M	$ 16.94M	$ 8.22M	$ 9.80M	$ 12.50M
Net Income From Continuing And Discontinued Operation	$ -10.25M	$ -13.58M	$ -16.39M	$ -8.09M	$ -7.10M	$ -10.81M
Normalized Income	$ -483.73K	-	-	$ -8.17M	$ -7.10M	$ -10.81M
Interest Expense	-	-	-	$ 4.19K	$ 325.00	$ 1.04K
EBIT	$ -7.56M	$ -13.69M	-	$ -8.08M	$ -7.00M	$ -10.72M
EBITDA	$ -5.16M	$ -13.65M	-	$ -8.04M	$ -6.95M	$ -10.69M

Currency in USD

Kiora Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing